Your current position:HOME > Products & Services > Tumor Gene Detection > Renal Cancer
Products & Services
Summary of Renal cancer
Renal cancer originates in the malignant tumor of the urinary tubular epithelial system of renal parenchyma. Because the diseased parts are hidden, usually the patients are already in advanced stage when the disease is found. At present, the morbidity of Renal cancer in our country is increasing by years, the ratio of men and women is about 2:1, the age of high morbidity is between 50 and 70. According to the latest statistic data, there were 66,800 new cases of Renal cancer in 2015.

Scientific studies have verified that cancer is caused by the genetic mutation of human body, genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore, it is regarded as a first choice for advanced cancer patients in multiple cancer types. Presently, the Everolimus, Axitinib, Sorafenib, Pazopanib, Sunitinib and so on have been approved by FDA/CFDA. But, the gene variations carried by different patients are different, which makes patients with different sensitivity, toxic and adverse effects for same antineoplastic drugs.

The precision diagnosis is a prerequisite for accurate medication. The idea of molecular genotype makes the doctors formulate best therapeutic regimen according to biomarkers carried by renal cancer patients and corresponding clinical status, to greatly find out potentially available targeted drugs and enhance treatment efficiency of antineoplastic drugs.

  The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.
Renal core™

Gene detection of individualized medication of Renal cancer

Buring Rock Renal core™, targeted at patients with Renal cancer, by applying the advanced second sequencing technique, can comprehensively detect drug-inhibited target gene related to Renal cancer, which clinically provides reference information of selection of individualized treatment for Renal cancer, so as to achieve the accurate treatment.

Genes covered in Renal core™


Targeted drugs covered in Renal core™


More comprehensive cancer individualized medication choice:

Renal core™ comprehensively detects drug-inhibited target gene suggested in Renal cancer NCCN guideline, drug-inhibited target spot researched in phase Ⅱ/Ⅲ clinical trial of Renal cancer and approved drug-inhibited target spot in all kinds of cancers, provides the most comprehensive genetic detecting of individualized medication of Renal cancer. 

More accurate gene mutation detection related to renal cancer:

The gene detection Panel based on the second generation sequencing technology optimized by Burning Rock Dx, can detect 4 types of variation types at one time (mutation, insertion and deletion, fusion, amplification, etc.), at the same time, applies deep sequencing to deeply cover trace genovariation, so as to provide full view of the precise genovariation although samples are limited. On the one hand, the parallel detecting with the polygenic high sensitivity  improves the detection rate of drug-inhibited genovariation, which is able to miss opportunity of dedication; On the other hand, the complete coverage of exons can detect the hot spots and rare even unknown genovariation at the same time in one detection, detect related drug-resistant mutation while discovering drug sensitivity mutation,  having an accurate reflection of the sensitivity and drug resistance information of the patients after the usage of medication.

More professional detection report interpretation:

Buring Rock Dx, having the patented automated analysis system, is also the domestic third party detecting company only owning the professional medical department. The improved software and hardware resources ensures the accuracy of every detection report, which provides accurate and comprehensive basis of designing more reasonable individualized treatment scheme for doctors.

Applicable Populations


Sample Requirements

Operation organization and biopsy samples, fresh tissues or paraffin embedding samples are available.

Service Cycle

After sample inspection, detailed detection report will be issued in 10 natural days.

Service Procedure

Cases Sharing